iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. Its Zio XT monitor, a single-use, wire-free, and wearable patch-based biosensor, records patient's heartbeats and ECG data. The company was founded in 2006 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IRTC
Previous Symbol
CUSIPN/A
Phone415-632-5700
Debt
Debt-to-Equity Ratio0.51
Current Ratio4.79
Quick Ratio4.69
Price-To-Earnings
Trailing P/E Ratio-51.42
Forward P/E Ratio-35.94
P/E GrowthN/A
Sales & Book Value
Annual Sales$98.51 million
Price / Sales16.41
Cash FlowN/A
Price / CashN/A
Book Value$3.46 per share
Price / Book19.32
Profitability
EPS (Most Recent Fiscal Year)($1.30)
Net Income$-29,420,000.00
Net Margins-33.79%
Return on Equity-62.85%
Return on Assets-36.11%
Miscellaneous
Employees575
Outstanding Shares24,180,000
Market Cap$1.80 billion
OptionableOptionable
Irhythm Technologies (NASDAQ:IRTC) Frequently Asked Questions
What is Irhythm Technologies' stock symbol?
Irhythm Technologies trades on the NASDAQ under the ticker symbol "IRTC."
How were Irhythm Technologies' earnings last quarter?
Irhythm Technologies Inc (NASDAQ:IRTC) issued its earnings results on Tuesday, October, 30th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.45) by $0.02. The business had revenue of $38.10 million for the quarter, compared to analysts' expectations of $35.87 million. Irhythm Technologies had a negative return on equity of 62.85% and a negative net margin of 33.79%. The company's quarterly revenue was up 52.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.29) EPS. View Irhythm Technologies' Earnings History.
When is Irhythm Technologies' next earnings date?
What price target have analysts set for IRTC?
9 brokerages have issued 1 year target prices for Irhythm Technologies' shares. Their forecasts range from $60.00 to $117.00. On average, they expect Irhythm Technologies' share price to reach $94.1429 in the next year. This suggests a possible upside of 33.3% from the stock's current price. View Analyst Price Targets for Irhythm Technologies.
What is the consensus analysts' recommendation for Irhythm Technologies?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Irhythm Technologies in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Irhythm Technologies.
What are Wall Street analysts saying about Irhythm Technologies stock?
Here are some recent quotes from research analysts about Irhythm Technologies stock:
- 1. According to Zacks Investment Research, "iRhythm Technologies, Inc. is a digital healthcare company. It focuses on the provision of ambulatory electrocardiogram, monitoring for patients at risk for arrhythmias primarily in the United States. The company offers ZIO Service, a platform which provides wearable biosensor with cloud-based data analytics that distill data from heartbeats into clinically actionable information. iRhythm Technologies, Inc. is headquartered in San Francisco, California. " (11/3/2018)
- 2. BTIG Research analysts commented, "Enthusiasm iRhythm reported revenue of $35.5M, 8.5% above our estimate. Though mgmt continues to see a healthy balance of new and same-store account growth, it appears there is an increasing benefit from cross-selling with ZIO AT as well as growing success within large systems. Commentary appeared more bullish about the opportunity with management noting having completed the hiring of 110 reps for the full year in the quarter. Mgmt raised expense guidance again by 12% at the midpoint, outpacing the guidance change on the revenue side. Though we think there is little risk in the near-term to growing 50%+, a sizeable expense base may be an area of scrutiny particularly among conservative funds more focused on a pathway to profitability." (8/2/2018)
- 3. Northland Securities analysts commented, "We note that this was a physician-initiated study and funded by Bardy. Also, it is important to take this study within the context of an initial study which could provide clues for a larger head-head study, providing important clues for the sensitivity & specificity of R-R wave vs. P-wave analysis in ambulatory ECG monitoring." (4/16/2018)
Has Irhythm Technologies been receiving favorable news coverage?
News coverage about IRTC stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Irhythm Technologies earned a news impact score of 1.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Who are some of Irhythm Technologies' key competitors?
Some companies that are related to Irhythm Technologies include Hill-Rom (HRC), Haemonetics (HAE), Globus Medical (GMED), ICU Medical (ICUI), Insulet (PODD), Penumbra (PEN), Integra Lifesciences (IART), Cantel Medical (CMD), Merit Medical Systems (MMSI), NuVasive (NUVA), Novocure (NVCR), Glaukos (GKOS), Tandem Diabetes Care (TNDM), Mazor Robotics (MZOR) and Atrion (ATRI).
Who are Irhythm Technologies' key executives?
Irhythm Technologies' management team includes the folowing people:
- Mr. Kevin M. King, Pres, CEO & Director (Age 62)
- Mr. Matthew C. Garrett, Chief Financial Officer (Age 50)
- Mr. David A. Vort, Exec. VP of Sales (Age 52)
- Dr. Derrick Sung, Exec. VP of Strategy & Corp. Devel. (Age 45)
- Mr. Karim Karti, Chief Operating Officer (Age 49)
When did Irhythm Technologies IPO?
(IRTC) raised $76 million in an initial public offering (IPO) on Thursday, October 20th 2016. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.
Who are Irhythm Technologies' major shareholders?
Irhythm Technologies' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (9.35%), BlackRock Inc. (9.17%), FMR LLC (7.71%), Franklin Resources Inc. (4.10%), Wells Fargo & Company MN (3.46%) and Alliancebernstein L.P. (3.41%). Company insiders that own Irhythm Technologies stock include David A Vort, Derrick Sung, Kevin M King, Matthew C Garrett, Raymond W Scott, Synergy Life Science Partners and Vijay K Lathi. View Institutional Ownership Trends for Irhythm Technologies.
Which institutional investors are selling Irhythm Technologies stock?
IRTC stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Partner Fund Management L.P., FIL Ltd, Capital Research Global Investors, Perceptive Advisors LLC, Franklin Resources Inc., Bank of New York Mellon Corp and Columbus Circle Investors. Company insiders that have sold Irhythm Technologies company stock in the last year include David A Vort, Derrick Sung, Kevin M King, Matthew C Garrett, Raymond W Scott and Vijay K Lathi. View Insider Buying and Selling for Irhythm Technologies.
Which institutional investors are buying Irhythm Technologies stock?
IRTC stock was purchased by a variety of institutional investors in the last quarter, including Deutsche Bank AG, BlackRock Inc., Engineers Gate Manager LP, Man Group plc, Bellevue Group AG, First Trust Advisors LP, MetLife Investment Advisors LLC and Eaton Vance Management. View Insider Buying and Selling for Irhythm Technologies.
How do I buy shares of Irhythm Technologies?
Shares of IRTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Irhythm Technologies' stock price today?
One share of IRTC stock can currently be purchased for approximately $70.63.
How big of a company is Irhythm Technologies?
Irhythm Technologies has a market capitalization of $1.80 billion and generates $98.51 million in revenue each year. The company earns $-29,420,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis. Irhythm Technologies employs 575 workers across the globe.
What is Irhythm Technologies' official website?
How can I contact Irhythm Technologies?
Irhythm Technologies' mailing address is 650 TOWNSEND STREET SUITE 500, SAN FRANCISCO CA, 94103. The company can be reached via phone at 415-632-5700 or via email at [email protected]
MarketBeat Community Rating for Irhythm Technologies (NASDAQ IRTC)
MarketBeat's community ratings are surveys of what our community members think about Irhythm Technologies and other stocks. Vote "Outperform" if you believe IRTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
